FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893259841> ?p ?o ?g. }

• W2893259841 endingPage "e0204495" @default.
• W2893259841 startingPage "e0204495" @default.
• W2893259841 abstract "New therapeutic strategies are needed to treat drug resistant tuberculosis (TB) and to improve treatment for drug sensitive TB. Pyrazinamide (PZA) is a critical component of current first-line TB therapy. However, the rise in PZA-resistant TB cases jeopardizes the future utility of PZA. To address this problem, we used the guinea pig model of TB and tested the efficacy of an inhaled dry powder combination, referred to as Pyrazinoic acid/ester Dry Powder (PDP), which is comprised of pyrazinoic acid (POA), the active moiety of PZA, and pyrazinoic acid ester (PAE), which is a PZA analog. Both POA and PAE have the advantage of being able to act on PZA-resistant Mycobacterium tuberculosis. When used in combination with oral rifampicin (R), inhaled PDP had striking effects on tissue pathology. Effects were observed in lungs, the site of delivery, but also in the spleen and liver indicating both local and systemic effects of inhaled PDP. Tissue granulomas that harbor M. tuberculosis in a persistent state are a hallmark of TB and they pose a challenge for therapy. Compared to other treatments, which preferentially cleared non-necrotic granulomas, R+PDP reduced necrotic granulomas more effectively. The increased ability of R+PDP to act on more recalcitrant necrotic granulomas suggests a novel mechanism of action. The results presented in this report reveal the potential for developing therapies involving POA that are optimized to target necrotic as well as non-necrotic granulomas as a means of achieving more complete sterilization of M. tuberculosis bacilli and preventing disease relapse when therapy ends." @default.
• W2893259841 created "2018-10-05" @default.
• W2893259841 creator A5011461309 @default.
• W2893259841 creator A5017514393 @default.
• W2893259841 creator A5024313665 @default.
• W2893259841 creator A5026758522 @default.
• W2893259841 creator A5030435181 @default.
• W2893259841 creator A5045374465 @default.
• W2893259841 creator A5062608685 @default.
• W2893259841 creator A5064959859 @default.
• W2893259841 creator A5066867417 @default.
• W2893259841 creator A5071846305 @default.
• W2893259841 creator A5081406792 @default.
• W2893259841 date "2018-09-27" @default.
• W2893259841 modified "2023-09-26" @default.
• W2893259841 title "Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis" @default.
• W2893259841 cites W128341503 @default.
• W2893259841 cites W1414898727 @default.
• W2893259841 cites W1484825513 @default.
• W2893259841 cites W1634196889 @default.
• W2893259841 cites W1807960484 @default.
• W2893259841 cites W1853206387 @default.
• W2893259841 cites W1923394711 @default.
• W2893259841 cites W1964693504 @default.
• W2893259841 cites W1969365810 @default.
• W2893259841 cites W1971664672 @default.
• W2893259841 cites W1978243259 @default.
• W2893259841 cites W1978931755 @default.
• W2893259841 cites W1981824586 @default.
• W2893259841 cites W1986538901 @default.
• W2893259841 cites W1986815067 @default.
• W2893259841 cites W1991051142 @default.
• W2893259841 cites W2000710967 @default.
• W2893259841 cites W2002951011 @default.
• W2893259841 cites W2006545725 @default.
• W2893259841 cites W2008643985 @default.
• W2893259841 cites W2014965592 @default.
• W2893259841 cites W2023304660 @default.
• W2893259841 cites W2033776104 @default.
• W2893259841 cites W2041448568 @default.
• W2893259841 cites W2043598462 @default.
• W2893259841 cites W2046352089 @default.
• W2893259841 cites W2050026866 @default.
• W2893259841 cites W2050923812 @default.
• W2893259841 cites W2058889783 @default.
• W2893259841 cites W2075276272 @default.
• W2893259841 cites W2091439004 @default.
• W2893259841 cites W2096253034 @default.
• W2893259841 cites W2097583406 @default.
• W2893259841 cites W2098335911 @default.
• W2893259841 cites W2103716690 @default.
• W2893259841 cites W2106829237 @default.
• W2893259841 cites W2118543713 @default.
• W2893259841 cites W2127971692 @default.
• W2893259841 cites W2128835322 @default.
• W2893259841 cites W2129055298 @default.
• W2893259841 cites W2129221652 @default.
• W2893259841 cites W2129716166 @default.
• W2893259841 cites W2130518998 @default.
• W2893259841 cites W2138803339 @default.
• W2893259841 cites W2139451383 @default.
• W2893259841 cites W2140934532 @default.
• W2893259841 cites W2153562772 @default.
• W2893259841 cites W2157183580 @default.
• W2893259841 cites W2161340676 @default.
• W2893259841 cites W2163465871 @default.
• W2893259841 cites W2165648272 @default.
• W2893259841 cites W2166215411 @default.
• W2893259841 cites W2167156367 @default.
• W2893259841 cites W2168321453 @default.
• W2893259841 cites W2199646878 @default.
• W2893259841 cites W2220179525 @default.
• W2893259841 cites W2304750630 @default.
• W2893259841 cites W2325222543 @default.
• W2893259841 cites W2342118964 @default.
• W2893259841 cites W2344228894 @default.
• W2893259841 cites W2347055338 @default.
• W2893259841 cites W2413022520 @default.
• W2893259841 cites W2463635937 @default.
• W2893259841 cites W2528502090 @default.
• W2893259841 cites W2607003303 @default.
• W2893259841 cites W2949632495 @default.
• W2893259841 cites W36895966 @default.
• W2893259841 doi "https://doi.org/10.1371/journal.pone.0204495" @default.
• W2893259841 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6160074" @default.
• W2893259841 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30261007" @default.
• W2893259841 hasPublicationYear "2018" @default.
• W2893259841 type Work @default.
• W2893259841 sameAs 2893259841 @default.
• W2893259841 citedByCount "8" @default.
• W2893259841 countsByYear W28932598412018 @default.
• W2893259841 countsByYear W28932598412019 @default.
• W2893259841 countsByYear W28932598412020 @default.
• W2893259841 countsByYear W28932598412021 @default.
• W2893259841 countsByYear W28932598412022 @default.
• W2893259841 countsByYear W28932598412023 @default.
• W2893259841 crossrefType "journal-article" @default.
• W2893259841 hasAuthorship W2893259841A5011461309 @default.

• next